AstraZeneca PLC (AZN.L)
| Previous close | 10,250.00 |
| Open | 10,326.00 |
| Bid | 10,526.00 x 0 |
| Ask | 10,524.00 x 0 |
| Day's range | 10,308.00 - 10,578.00 |
| 52-week range | 7,870.00 - 11,000.00 |
| Volume | |
| Avg. volume | 2,801,238 |
| Market cap | 162.594B |
| Beta (5Y monthly) | 0.17 |
| PE ratio (TTM) | 130.68 |
| EPS (TTM) | N/A |
| Earnings date | N/A |
| Forward dividend & yield | 2.10 (2.04%) |
| Ex-dividend date | 24 Feb 2022 |
| 1y target est | N/A |
- Business Wire
First Patients Dosed in IRIS Phase III Trial Evaluating Anifrolumab in Lupus Nephritis
WILMINGTON, Del., May 27, 2022--The first patients have been dosed in the IRIS Phase III clinical trial of anifrolumab in lupus nephritis (LN).
- Business Wire
AstraZeneca aims to transform cancer care with practice-changing data at ASCO 2022
WILMINGTON, Del., May 23, 2022--AstraZeneca advances its ambition to redefine cancer care with new data to be presented across its diverse and industry-leading portfolio of cancer medicines at the American Society of Clinical Oncology (ASCO) Annual Meeting, June 3-7, 2022.
- Business Wire
PT027, a Novel Fixed-Dose Combination of Albuterol and Budesonide, Used as an As-Needed Rescue Medicine, Significantly Reduced the Risk of a Severe Exacerbation Compared to Albuterol by 27% in Patients With Asthma
WILMINGTON, Del., May 15, 2022--Full results from the positive MANDALA Phase III trial showed that PT027 (albuterol/budesonide) at two different strengths of budesonide, an inhaled corticosteroid (ICS), used as an as-needed rescue medicine, demonstrated a statistically significant reduction in the risk of a severe exacerbation versus albuterol rescue in patients with moderate to severe asthma.1,2
